RMD NYSE
ResMed Inc.
1W: +2.1%
1M: +12.9%
3M: +17.0%
YTD: +2.6%
1Y: -3.1%
3Y: +77.6%
5Y: +0.0%
$250.80
-2.40 (-0.95%)
Weekly Expected Move ±3.0%
$238
$245
$253
$260
$268
Credit Risk of going bust: lower than 92% of companies Debt: 2.3% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.43 (down 99.8%), ResMed Inc. would be worth roughly what it owes.
Total debt $825.9M against a stock market value of $35.27B.
Distance to default 15.31 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $459.7M (short-term plus half of long-term), stock volatility 28.8%; Altman Z 11.75. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.43 (down 99.8%), ResMed Inc. would be worth roughly what it owes.
Total debt $825.9M against a stock market value of $35.27B.
Distance to default 15.31 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $459.7M (short-term plus half of long-term), stock volatility 28.8%; Altman Z 11.75. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.45
Bullish
4 bullish
1 neutral
1 bearish
Articles (7d)
6
Daily Sentiment (7 Days)
Articles (100)
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Notable healthcare headlines for the week: Moderna, Roche, and Abbott Laboratories in focus
Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?
ResMed Set to Report Q1 Earnings: What's in the Cards for the Stock?
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Goldman's defensive stocks with quality-growth characteristics
ResMed Inc. $RMD Shares Sold by Baird Financial Group Inc.
Healthcare stocks with the strongest dividend growth grades
Bank of America Corp DE Buys New Stake in ResMed Inc. $RMD
Engineers Gate Manager LP Has $1.58 Million Stake in ResMed Inc. $RMD
Is This the Right Time to Retain Resmed Stock in Your Portfolio?
ResMed upgraded at RBC Capital Markets on Q4 positives
ResMed Inc. $RMD Shares Purchased by Hsbc Holdings PLC
Notable healthcare headlines for the week: UnitedHealth, Moderna, and Medtronic in focus
AlphaGrep UK Ltd Takes $544,000 Position in ResMed Inc. $RMD
Ten healthcare stocks leading in year-over-year CapEx growth
Notable healthcare headlines for the week: Veeva Systems, Boston Scientific in focus
Canada Pension Plan Investment Board Buys New Position in ResMed Inc. $RMD
228,458 Shares in ResMed Inc. $RMD Purchased by American Capital Management Inc.
228,458 Shares in ResMed Inc. $RMD Purchased by American Capital Management Inc.
Notable healthcare headlines for the week: Eli Lilly, Hims & Hers Health, and Merck in focus
87,722 Shares in ResMed Inc. $RMD Purchased by Avalon Trust Co
41,381 Shares in ResMed Inc. $RMD Acquired by ABN AMRO Bank N.V.
ResMed (RMD) Q4 2026 Earnings Call Transcript
Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists
Should Investors Buy Inogen as Low Valuation Meets Execution Risk?
RMD Stock Down Despite Q4 Earnings Beat, Revenues Rise Y/Y
ResMed expects FY 2027 revenue of $5.75B-$5.85B and non-GAAP EPS of $12-$12.25 while accelerating $1.85B+ shareholder returns
ResMed (RMD) Q4 Earnings and Revenues Top Estimates
Is INSP a Buy as Margins Improve but Reimbursement Risks Persist?
INSP's 28.1% Past-Month Rally Raises a Key Question for Investors
What to Expect From These 2 MedTech Stocks This Earnings Season?
Curious about ResMed (RMD) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Viemed Healthcare, Inc. (VMD) Lags Q2 Earnings Estimates
Resmed's Q4 Earnings on Deck: What's in Store for the Stock?
BankChampaign National Association Acquires New Shares in ResMed Inc. $RMD
ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth
Baxter International (BAX) Surpasses Q2 Earnings and Revenue Estimates
American Capital Management Inc. Has $59.58 Million Position in ResMed Inc. $RMD
Baader Bank Aktiengesellschaft Trims Position in ResMed Inc. $RMD
ResMed downgraded at RBC Capital Markets on FY27 challenges
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term
Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?
ResMed (RMD) Soars 4.2%: Is Further Upside Left in the Stock?
Here's Why ResMed (RMD) is a Strong Growth Stock
ResMed (RMD) Upgraded to Buy: Here's Why
Wall Street Analysts Think ResMed (RMD) Could Surge 28.21%: Read This Before Placing a Bet
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Are Options Traders Betting on a Big Move in ResMed Stock?
Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday
This ResMed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Delta Air Lines To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday
ResMed downgraded at Morgan Stanley on Philips re-entry and GLP-1 headwinds
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Is This the Right Time to Retain Resmed Stock in Your Portfolio?
Notable healthcare headlines for the week: UnitedHealth, Medtronic, and Eli Lilly in focus
Notable healthcare headlines for the week: UnitedHealthcare, Pfizer, Eli Lilly in focus
ResMed (RMD) is a Top-Ranked Growth Stock: Should You Buy?
Is the Options Market Predicting a Spike in ResMed Stock?
Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
Silver Economy Investing: Why the Healthcare Giants Are in Focus
Jim Cramer Warns This Market Is Far More Brutal Than Dot-Com Bubble Era: 'The Difference Between Now And 1999 Is...'
Here's Why ResMed (RMD) is a Strong Growth Stock
Healthcare earnings impress with 86% beat rate, yet sector lags: Earnings Scorecard
ResMed declares $0.60 dividend
RMD Stock Down Despite Q3 Earnings & Revenue Beat, Margins Rise
ResMed expects FY 2026 gross margin of 62%-63% as it plans $175M+ Q4 buybacks and targets June 1 close for $340M Noctrix deal
ResMed (RMD) Q3 2026 Earnings Transcript
Transcript: ResMed Q3 2026 Earnings Conference Call
ResMed (RMD) Surpasses Q3 Earnings and Revenue Estimates
ResMed (RMD) Reports Q3 Earnings: What Key Metrics Have to Say
ResMed announces CFO succession
Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor
Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026
Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026
Here are the major earnings after the close Thursday
Earnings Scheduled For April 30, 2026
Wall Street's Insights Into Key Metrics Ahead of ResMed (RMD) Q3 Earnings
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Arizona State Retirement System Trims Stock Position in ResMed Inc. $RMD
ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth
Resmed's Q3 Earnings on Deck: What's in Store for the Stock?
Why ResMed (RMD) is Poised to Beat Earnings Estimates Again
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Lbp Am Sa Buys 18,142 Shares of ResMed Inc. $RMD
Should You Continue to Hold Resmed Stock in Your Portfolio?
Abbott stock slips on guidance cut, ranks 10th in healthcare equipment Quant ratings
Aaron Wealth Advisors LLC Sells 2,210 Shares of ResMed Inc. $RMD
Azzad Asset Management Inc. ADV Has $1.08 Million Stock Position in ResMed Inc. $RMD
4,837 Shares in ResMed Inc. $RMD Acquired by Runnymede Capital Advisors Inc.
4,837 Shares in ResMed Inc. $RMD Acquired by Runnymede Capital Advisors Inc.
GraniteShares Advisors LLC Has $58,000 Stock Holdings in ResMed Inc. $RMD
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Sells 2,674 Shares of ResMed Inc. $RMD
Element Squared LLC Buys Shares of 6,067 ResMed Inc. $RMD
Aberdeen Group plc Sells 37,737 Shares of ResMed Inc. $RMD
Banque Pictet & Cie SA Sells 4,207 Shares of ResMed Inc. $RMD